Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish biotechnology research company Tripep AB has achieved additional positive results in pre-clinical trials of its investigational hepatitis C vaccine, ChronVac-C DNA, combined with a DNA delivery system developed by Inovio Biomedical Corporation.
Subscribe to our email newsletter
Ongoing toxicity studies of ChronVac-C delivered using Inovio’s electroporation-based system revealed that the combination induces a humoral response in rabbits that is comparable to results previously observed in mice.
“These results provide encouragement that the combination of ChronVac-C with the MedPulser DNA delivery system may work well in humans and indicate that our collaboration with Inovio is progressing very well,” said Tripep’s CEO, Jan Nilsson.
Hepatitis is a disease characterized by inflammation of the liver. Hepatitis C virus (HCV) is spread primarily by direct contact with human blood, the major causes worldwide being the use of unscreened blood transfusions, and re-use of needles and syringes that have not been adequately sterilized.